Foundation for Innovative New Diagnostics (FIND)

Enables the development of diagnostic tests for poverty-related diseases and reduces barriers between technology and implementation of diagnostic solutions in low-income countries

  • 80G
  • 12A
Transparency Rating:
Transparency Rating
The transparency rating is calculated based on the amount of information available for the organisation.
Claim this profile

About

  • Headquarters

    New Delhi, Delhi

  • Since

    2015

Provides and demonstrates new, rapid, quality-assured tests for tuberculosis (TB) at low prices for the public health sector. Its activities include e Read morevaluation and demonstration studies of new diagnostic tools that FIND had co-developed with partners which include liquid culture and drug susceptibility testing, rapid speciation, molecular line probe assay, LED-based fluorescence microscopy and Xpert MTB/RIF. The strategy to create diagnostic solutions is structured around four main themes which include Catalyse development which is the need to identify relevant diagnostic solutions and remove barriers to their development, Guide use & inform policy which aims to lead products through the clinical trials pathway to market entry, Accelerate access which aims to support the appropriate use of diagnostics to achieve health impact and lastly Shape agenda which focuses on understanding of the value of diagnostics. Additionally, the organisation collects and analyses data from the studies conducted in India which is supported by the World Health Organisation (WHO), which had led to the new Revised National TB Control Programme (RNTCP) to formulate guidelines for the detection and management of drug-resistant TB. Presently, FIND also monitors Hepatitis-C alongside a strong continued focus on TB diagnosis.

Programs

  • Antimicrobial resistance

    Attempts to tackle antimicrobial resistance (AMR) to preserve the effectiveness of antibiotic drugs and save lives. Works towards enhancing access to AMR testing at primary care level to prevent further development of AMR. In hospitals, the aim is to improve diagnosis for severe bloodstream infections and neonatal sepsis to reduce AMR-related deaths. Additionally, it also supports the development of digital tools for AMR surveillance and antimicrobial stewardship, following the One Health approach.

  • Neglected Tropical Diseases

    Our goal is to accelerate the elimination of neglected tropical diseases (NTDs) by implementing tailored testing strategies. NTDs, a diverse group of 20 diseases, disproportionately affect marginalized communities, especially women and children. The organisation’s NTD strategy focuses on improving diagnosis and surveillance for diseases like Buruli ulcer, Chagas disease, sleeping sickness, visceral leishmaniasis, lymphatic filariasis, onchocerciasis, and schistosomiasis. It collaborates with partners to establish a transparent diagnostic pipeline aligned with WHO NTD 2021-2030 roadmap, advocate for critical product and funding support, develop novel rapid diagnostic tests, support local production of diagnostic tests, evaluate new diagnostic tests for certain NTDs, create specimen banks, and strengthen country capacity for testing in endemic areas.

  • Women’s health

    The organisation’s cervical cancer strategy focuses on helping countries achieve the WHO's goal of eliminating cervical cancer as a public health problem. This is done by promoting the rapid adoption of HPV-based cervical screening and implementing women-centered screening models in low- and middle-income countries. The organisation collaborates with partners to support community-led advocacy and education to scale up screening, accelerate the adoption of women-centric technology, and improve access to affordable screening tests. The aim is to increase screening rates and save lives from cervical cancer.

  • Tuberculosis

    The organisation’s TB strategy aims to reduce the diagnostic gap by developing new tests and improving community-based testing. It also focuses on integrated testing for respiratory symptoms to detect missed TB cases and similar conditions like COVID-19. Collaborates with partners to expand resources for TB diagnostics, evidence dossiers for policy evaluation, new TB tests, and molecular testing uptake.

Leadership Team

  • Sarabjit Chadha

    Regional Technical Director

  • Rajashree Sen

    Senior Manager,Country Programmes

  • Krithika Raghavan

    Senior Manager,G20 Engagement

  • Sanjay Sarin

    VP, Access

Demographics & Structure

  • No. of Employees

    21-50

M&E

  • Internal, External Assessors

    No

Policies

  • Ethics and Transparency Policies

    No

  • Formal CEO Oversight & Compensation Policy

    No

Political & Religious Declarations

  • On Affiliation if any

    No

  • On Deployment Bias if any

    No

Registration Details

  • Registration ID

    U73100DL2015NPL282471

  • VO ID / Darpan ID

    DL/2017/0174792

  • 12A

    AACCF6112DE20169

  • 80G

    AACCF6112DF20167

  • FCRA

    Not Available

  • CSR Registration Number

    Not Available

Location

  • Headquarters

    Flat No. 8, 9th Floor, Vijaya Building 17 Barakhamba Road New Delhi,India, 110001

    Directions
  • Offices in Cities

Other Details

  • Parent Organisation

    Central TB Division, Ministry of Health and Family Welfare

  • Type & Sub Type

    Non-profit
    Section 8 (formerly Section 25)